Profile data is unavailable for this security.
About the company
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
- Revenue in USD (TTM)11.13m
- Net income in USD-81.99m
- Incorporated2007
- Employees160.00
- LocationCapricor Therapeutics Inc10865 Road to the Cure, Suite 150SAN DIEGO 92121United StatesUSA
- Phone+1 (310) 358-3200
- Fax+1 (302) 655-5049
- Websitehttps://capricor.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sana Biotechnology Inc | 0.00 | -234.41m | 1.11bn | 194.00 | -- | 5.57 | -- | -- | -0.9708 | -0.9708 | 0.00 | 0.7447 | 0.00 | -- | -- | 0.00 | -47.13 | -39.42 | -51.39 | -43.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.82 | -- | 5.06 | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 1.11bn | 55.00 | -- | 2.39 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.40m | -155.09m | 1.13bn | 156.00 | -- | -- | -- | 805.00 | -10.02 | -10.02 | 0.0905 | -- | 0.007 | -- | 4.96 | 8,974.36 | -77.54 | 114.91 | -96.94 | 138.28 | -- | -- | -11,077.57 | 4,710.68 | -- | -199.52 | 0.7307 | -- | -88.89 | -56.75 | 799.19 | -- | 7.49 | -- |
| AbCellera Biologics Inc | 75.13m | -146.41m | 1.16bn | 562.00 | -- | 1.19 | -- | 15.41 | -0.4905 | -0.4905 | 0.2515 | 3.22 | 0.0553 | -- | 1.63 | 133,677.90 | -10.78 | -2.09 | -11.36 | -2.26 | -- | -- | -194.89 | -14.33 | 11.23 | -- | 0.00 | -- | 160.56 | -20.27 | 10.10 | -- | 23.86 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.19bn | 3.00k | 41.33 | 0.6934 | 13.93 | 2.00 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Savara Inc | 0.00 | -115.65m | 1.22bn | 59.00 | -- | 11.01 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.23bn | 160.00 | -- | 14.64 | -- | 110.33 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.23bn | 1.01k | 18.92 | -- | 11.75 | 2.15 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.24bn | 73.00 | -- | 5.67 | -- | 196.65 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -227.32m | 1.27bn | 130.00 | -- | 4.14 | -- | -- | -3.52 | -3.52 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -51.05 | -- | -55.64 | -- | -- | -- | -- | -- | -- | -33.78 | 0.1957 | -- | -- | -- | -91.13 | -- | -- | -- |
| Septerna Inc | 22.05m | -58.81m | 1.28bn | 75.00 | -- | 3.29 | -- | 58.17 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.34bn | 54.00 | -- | 5.54 | -- | 442.12 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.35bn | 147.00 | 73.84 | 4.65 | 46.08 | 7.43 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.35bn | 69.00 | -- | 2.64 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Capricor Therapeutics Inc's reporting currency: US Dollar USD
33.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 19 Feb 2026 | 3.42m | 6.28% |
| Tang Capital Management LLCas of 16 Jan 2026 | 3.40m | 6.25% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.61m | 4.80% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.24m | 4.11% |
| Point72 Asset Management LPas of 31 Dec 2025 | 1.84m | 3.38% |
| RA Capital Management LPas of 31 Dec 2025 | 1.51m | 2.77% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.02m | 1.87% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 829.52k | 1.53% |
| Darwin Global Management Ltd.as of 31 Dec 2025 | 800.00k | 1.47% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 730.88k | 1.34% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
